EVE (NYSE:EVEX – Get Free Report) had its price target lowered by equities research analysts at Canaccord Genuity Group from $9.00 to $8.50 in a report released on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 159.94% from the company’s current price.
Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $7.00 price objective on shares of EVE in a research note on Monday.
Read Our Latest Stock Report on EVE
EVE Price Performance
EVE (NYSE:EVEX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter. On average, analysts predict that EVE will post -0.53 EPS for the current year.
Hedge Funds Weigh In On EVE
An institutional investor recently raised its position in EVE stock. Strs Ohio grew its stake in Eve Holding, Inc. (NYSE:EVEX – Free Report) by 3,883.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,800 shares of the company’s stock after acquiring an additional 46,600 shares during the period. Strs Ohio’s holdings in EVE were worth $349,000 at the end of the most recent reporting period. 1.27% of the stock is owned by institutional investors and hedge funds.
About EVE
Eve Holding, Inc, together with its subsidiaries, develops urban air mobility solutions. It is involved in the design and production of electrical vertical take-off and landing vehicles (eVTOLs); provision of eVTOL service and support capabilities, including material services, maintenance, technical support, training, ground handling, and data services; and development of urban air traffic management systems.
See Also
- Five stocks we like better than EVE
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- RXO Shares Surge Following New Acquisition Deal
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- How to Use the MarketBeat Excel Dividend Calculator
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for EVE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EVE and related companies with MarketBeat.com's FREE daily email newsletter.